Paper - WANFANG MED ONLINE

You Position: Home > Paper

Current status of HIV protease inhibitors

( views:241, downloads:36 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 5

DOI:: 10.3321/j.issn:0513-4870.2005.05.002

Key Word:: 艾滋病;HIV;蛋白酶抑制剂

Abstract： @@ 艾滋病(acquired immunodeficiency syndrome,AIDS)是由人免疫缺陷病毒(human immunodeficiency virus,HIV)感染导致人体免疫机能缺陷,而易于发生机会性感染和肿瘤的临床综合征[1].在过去的20多年里造成2000多万人死亡,目前全世界艾滋病病毒感染者已达4000万左右[2].

Reference

[1]AS Fauci.The human immunodeficiency virus: infectivity and mechanisms of pathogenesis[J].1988,239 (4840).
[2]King NM,Schiffer CA,Prabu-Jeyabalan M,etc.Combating susceptibility to drug resistance: Lessons from HIV-1 protease[J].2004,11(10).
[3]Strohbach JW,Chrusciel RA.Non-peptidic HIV protease inhibitors.[J].2004,4(10).
[4]De Lucca G.V.,Lam P.Y.S..De novo design, discovery and development of cyclic urea HIV protease inhibitors[J].1998.
[5]Saurabh, Mehandru,Martin, Markowitz.Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection.[J].2003,12(11).
[6]Chmielewski J,Bowman MJ.Crucial amides for dimerization inhibitors of HIV-1 protease.[J].2004,14(6).
[7]Ledecq M,Lebon F.Approaches to the design of effective HIV-1 protease inhibitors.[J].2000,7(4).
[8]Gago F,Rodriguez Barrios F.HIV protease inhibition: limited recent progress and advances in understanding current pitfalls.[J].2004,4(9).
[9]Alexander Wlodawer,Alla Gustchina.Structural and biochemical studies of retroviral proteases[J].2000,1477(1/2).
[10]Bosi S,Spalluto G,Prato M,etc.Fullerene derivatives: an attractive tool for biological applications.[J].2003,38(11).
[11]Shaomeng Wang,G. W. A. Milne,Xinjian Yan,etc.Discovery of Novel, Non-Peptide HIV-1 Protease Inhibitors by Pharmacophore Searching[J].1996,39(10).
[12]S, Thaisrivongs,P K, Tomich,K D, Watenpaugh,etc.Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.[J].1994,37(20).
[13]VanderRoest S,Lunney EA,Gracheck SJ,etc.4-Hydroxy-5,6-dihydropyrones as inhibitors of HIV protease: the effect of heterocyclic substituents at C-6 on antiviral potency and pharmacokinetic parameters.[J].2001,44(14).
[14]RA Kramer,MD Schaber,AM Skalka,etc.HTLV-III gag protein is processed in yeast cells by the virus pol-protease[J].1986,231 (4745).
[15]Nicole Boggetto,Michele Reboud-Ravaux.Dimerization Inhibitors of HIV-1 Protease[J].2002,383(9).
[16]Kincaid JF,Mitsuya H,Maeda K,etc.Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.[J].2003,47(10).
[17]Soucek M,Konvalinka J,Prejdova J.Determining and Overcoming Resistance to HIV Protease Inhibitors.[J].2004,4(2).
[18]Boyer FE,Steinbaugh BA,Graham N,etc.Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.[J].1999,7(12).
[19]Randolph JT,DeGoey DA.Peptidomimetic inhibitors of HIV protease.[J].2004,4(10).
[20]Young J,Bucher HC,Battegay M.Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.[J].2004,54(2).
[21]Rozzelle JE,Craik CS,Dauber DS,etc.Macromolecular inhibitors of HIV-1 protease. Characterization of designed heterodimers.[J].2000,275(10).
[22]Peter J, Piliero.Atazanavir: a novel HIV-1 protease inhibitor.[J].2002,11(9).
[23]Seitz SP.,Lam PYS.,Rodgers JD.,etc.Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors[J].1998,5(10).
[24]Stephen, Becker,Lorna, Thornton.Fosamprenavir: advancing HIV protease inhibitor treatment options.[J].2004,5(9).
[25]Suvit Thaisrivongs,Harvey I. Skulnick,Steve R. Turner,etc.Structure-Based Design of HIV Protease Inhibitors: Sulfonamide-Containing 5,6-Dihydro-4-hydroxy-2-pyrones as Non-Peptidic Inhibitors[J].1996,39(22).
[26]Patel M,Klabe RM,Trainor GL,etc.Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.[J].2003,13(4).
[27]P Y, Lam,P K, Jadhav,C J, Eyermann,etc.Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors.[J].1994,263(5145).
[28]Klein LL,Kempf DJ,Randolph JT,etc.Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.[J].2004,14(15).
[29]Abdel Rahman HM,El Koussi NA,Al Karamany GS,etc.HIV Protease Inhibitors: Peptidomimetic Drugs and Future Perspectives.[J].2002,9(21).
[30]Patrick Y. S. Lam,Yu Ru,Prabhakar K. Jadhav,etc.Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2‘ Structure-Activity Relationship, and Molecular Recognition of Cyclic Ureas[J].1996,39(18).
[31]C N, Hodge,P E, Aldrich,L T, Bacheler,etc.Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.[J].1996,3(4).